# Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

> **NCT05696366** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 24 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Sotagliflozin
- **DRUG:** Volagidemab

## Key facts

- **NCT ID:** NCT05696366
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696366, "Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05696366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*